AUS
NZ
UK
CA
USA
IND
Inqo Investments Limited (INQO), a South African impact investment firm, announced that its Executive Chairman, Dr Kim Sze Tan, has converted longstanding interest-free shareholder loans totaling US$50,000 and R276,000 into ordinary shares following approval from the South African Reserve Bank. This conversion issued 91,435 new ordinary shares at 55 pence each, representing about 0.56% of the total issued share capital, underscoring Dr Tan's sustained confidence in Inqo's long-term strategy and growth prospects.
Key Points
- Inqo Investments Limited (INQO) is a South African impact investment company listed on the AQSE Growth Market.
- Executive Chairman Dr Kim Sze Tan converted longstanding interest-free shareholder loans into equity after receiving South African Reserve Bank approval.
- The conversion includes US$50,000 from Eastgate Investments Ltd (controlled by Dr Tan) and R276,000 in shareholder funding, resulting in 91,435 new ordinary shares issued at 55 pence per share—a 10% discount to the prevailing market price.
- The 91,435 new shares represent approximately 0.56% of Inqo's total issued share capital, with admission to the AQSE Growth Market expected on 31 July 2026.
- Post-conversion, Inqo's total issued share capital will be 16,463,066 ordinary shares, each with one voting right.
- Dr Tan's equity stake has increased, aligning his interests with other shareholders and strengthening the company’s balance sheet by eliminating shareholder loan liabilities.
Details of Converted Related Party Loans
The converted loans consist of two interest-free, unsecured facilities supporting Inqo’s working capital. The first is a US$50,000 convertible loan advanced in 2013 by Eastgate Investments Ltd, controlled by Dr Kim Sze Tan. The second is a R276,000 shareholder loan directly provided by Dr Tan. Both loans carried no interest and no collateral, reflecting his long-term commitment to the company’s operational and strategic needs.
These loans have been vital in maintaining Inqo’s working capital since 2013. Their conversion into equity removes these liabilities from the balance sheet and increases Dr Tan’s ownership, aligning his financial interests with those of other shareholders. Further details are available in Inqo’s Audited Group Results for the financial year ended 2026.
Conversion Terms and Issuance of 91,435 New Shares
The loans were converted at a fixed price of 55 pence per ordinary share, representing a 10% discount to the market price at conversion, as stipulated in the loan agreements. The US$50,000 loan conversion resulted in 68,122 new shares, while the R276,000 loan conversion issued 23,313 shares, totaling 91,435 new ordinary shares (the "Conversion Shares").
These fully paid Conversion Shares were issued to Springhill Management Limited, a company wholly owned by Dr Tan acting as nominee. The new shares rank equally with existing ordinary shares, carrying identical rights and entitlements. This transaction extinguished the related loan liabilities, improving Inqo’s financial position.
Regulatory Approval and Related Party Transaction Compliance
The conversion qualifies as a related party transaction under Rule 4.6 of the AQSE Growth Market Access Rulebook because Dr Tan is Executive Chairman and a substantial shareholder, and Eastgate Investments Ltd is controlled by him. The transaction underwent appropriate board scrutiny and shareholder safeguards.
Dr Tan abstained from board discussions and approval regarding the conversion to maintain independence. Independent directors assessed the terms as fair and reasonable to shareholders. The conversion was treated as inside information under the Market Abuse (Amendment) (EU Exit) Regulations 2019/310 until SARB approval was obtained and the announcement was made.
Strategic Rationale and Executive Chairman’s Statement
Dr Kim Sze Tan expressed confidence in Inqo’s long-term strategy, noting his ongoing support through this conversion. By exchanging shareholder loans for equity, the company strengthens its balance sheet and increases his personal investment, signaling commitment to long-term shareholder value.
This conversion reduces fixed obligations, improves debt-to-equity ratios, and removes contingent liabilities, enhancing financial flexibility for operations and future investments. Dr Tan’s choice to convert loans into equity rather than maintain debt underscores his belief in the company’s growth potential.
Impact on Share Capital and Voting Rights
Following admission of the 91,435 Conversion Shares to the AQSE Growth Market, Inqo’s issued share capital will total 16,463,066 ordinary shares, each with one voting right. The company holds no treasury shares, so all shares carry full voting rights. This total represents the denominator for shareholder notification requirements under FCA Disclosure Guidance and Transparency Rules.
The 0.56% increase in share capital from the conversion is modest, reflecting the long-term nature of the loans. This limited dilution is unlikely to significantly affect existing voting control but increases Dr Tan’s stake via Springhill Management Limited.
Admission Timeline and Trading Commencement
Admission of the Conversion Shares to trading on the AQSE Growth Market is expected at 8:00 a.m. on 31 July 2026. This date marks when the shares become tradable and are included in total issued share capital for governance and disclosure purposes. The 28 July 2026 announcement provided advance notice to shareholders and the market.
This clear admission date enables investors to plan disclosures accurately under FCA rules, ensuring orderly market operations and transparency.
About Inqo Investments Limited
Inqo Investments Limited, registered under company number 1998/024741/06 with share code INQO and ISIN ZAU000014391, is a South African impact investment company listed on the AQSE Growth Market. The company focuses on investments that deliver financial returns alongside positive social and environmental impacts.
Being domiciled in South Africa, Inqo’s corporate actions, including loan conversions, are regulated by South African authorities such as the South African Reserve Bank, whose approval was required and obtained for this transaction. Listing on the AQSE Growth Market provides access to UK and international capital but does not override South African regulatory oversight.
Financial and Capital Structure Implications
The announcement does not disclose Inqo’s full financial metrics but reveals reliance on related party financing totaling US$50,000 and R276,000 in interest-free loans since 2013. This underscores Dr Tan’s significant financial support for working capital and operations.
Converting these loans into equity improves leverage ratios and reduces related party obligations, potentially enhancing creditworthiness and financial flexibility. It also reflects confidence in Inqo’s operational maturity and future share price appreciation.
Governance and Director Independence in Related Party Approvals
Corporate governance protocols were strictly followed, with Dr Tan excluded from board deliberations on the conversion. Independent directors determined the terms to be fair and reasonable, ensuring shareholder protection. This approach aligns with AQSE Growth Market rules and exemplifies best practices in managing related party transactions.
The 10% discount conversion price was deemed appropriate and did not unfairly benefit the Executive Chairman at shareholders’ expense.
This article is for informational purposes only and does not constitute investment advice. It is based solely on the official RNS announcement by Inqo Investments Limited and summarizes disclosed facts. Readers should seek independent financial advice tailored to their circumstances before making investment decisions. Share prices and market conditions can fluctuate rapidly, and past performance is not indicative of future results. Verification of the AQSE Growth Market’s suitability and regulatory status is recommended.
